Fel d 1–derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: A randomized, placebo-controlled study - 27/12/12
, Peter Couroux, MD a, , Pascal Hickey, PhD b, Anne Marie Salapatek, PhD a, ‡, Paul Laidler, PhD c, Mark Larché, PhD d, Roderick P. Hafner, PhD c, ⁎ 
Corresponding author: Roderick P. Hafner, PhD, Circassia Limited, Magdalen Centre, The Oxford Science Park, Oxford OX4 4GA, United Kingdom.Abstract |
Background |
Allergic rhinoconjunctivitis is an increasingly common source of morbidity, with sensitivity to cats accounting for 10% to 15% of disease burden. Allergy to cats is also a major risk factor for the development of asthma.
Objectives |
We sought to probe the persistence of the treatment effect of a novel Fel d 1–derived peptide antigen desensitization (Cat-PAD) 1 year after the start of treatment in subjects with cat allergy–induced rhinoconjunctivitis after standardized allergen challenge.
Methods |
In a randomized, double-blind, placebo-controlled, parallel-group clinical trial, subjects attended an environmental exposure chamber in which they were exposed to cat allergen before and after treatment with 2 different regimens of Cat-PAD over a 3-month period. Clinical efficacy was assessed as a change in total rhinoconjunctivitis symptom scores 18 to 22 weeks and 50 to 54 weeks after the start of treatment.
Results |
Treatment with Cat-PAD showed greater efficacy with 4 administrations of a 6-nmol dose 4 weeks apart than with 8 administrations of a 3-nmol dose 2 weeks apart. The treatment effect of 6 nmol persisted 1 year after the start of treatment and was significantly different from that of 3 nmol (P = .0342) and placebo (P = .0104). The treatment effect was apparent on both nasal and ocular symptoms at 1 year.
Conclusions |
A short course of Cat-PAD improves the ocular and nasal components of rhinoconjunctivitis symptoms in subjects with cat allergy, with the treatment effect persisting 1 year after the start of treatment.
Le texte complet de cet article est disponible en PDF.Key words : Allergic rhinitis, allergic rhinoconjunctivitis, cat allergy, environmental exposure chamber, Fel d 1 peptide immunotherapy, T-cell epitope, immune tolerance, persistence
Abbreviations used : AE, EEC, PAD, PTC, TEAE, TNSS, TOSS, TRSS
Plan
| Supported by Adiga Life Sciences and Circassia. M.L. is supported by the Canada Research Chairs program, the Canadian Foundation for Innovation, and the McMaster University/GlaxoSmithKline Chair in Lung Immunology at St Joseph’s Healthcare. |
|
| Disclosure of potential conflict of interest: D. Patel and P. Couroux are employed by Cetero Research. P. Hickey, P. Laidler, and R. P. Hafner are employed by Circassia Limited. A. M. Salapatek was employed by Cetero Research and has received research support from Circassia Research. M. Larché is founder, consultant, and stockholder of Circassia Limited; is scientific founder of Adiga Life Sciences; has consultant arrangements with Boehringer Ingelheim; has received one or more honoraria from MedImmune; has received research support from Adiga Life Sciences, the Canadian Institutes for Health Research, the Canadian Lung Association, the Canada Research Chairs program, and the McMaster University/GlaxoSmithKline Chair in Lung Immunology at St Joseph’s Healthcare; and is a member of the American Academy of Allergy, Asthma & Immunology Genetics, Molecular Biology, and Epidemiology Committee. |
Vol 131 - N° 1
P. 103 - janvier 2013 Retour au numéro
Article précédent
- Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy
- Marija Geroldinger-Simic, Tamar Kinaciyan, Birgit Nagl, Ursula Baumgartner-Durchschlag, Hans Huber, Christof Ebner, Jonas Lidholm, Detlef Bartel, Stefan Vieths, Beatrice Jahn-Schmid, Barbara Bohle
- Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma
- Philippe Gevaert, Lien Calus, Thibaut Van Zele, Katrien Blomme, Natalie De Ruyck, Wouter Bauters, Peter Hellings, Guy Brusselle, Dirk De Bacquer, Paul van Cauwenberge, Claus Bachert
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?